Wegovy (semaglutide 2.4mg) is the first GLP-1 receptor agonist FDA-approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Administered as a once-weekly injection at doses from 0.25mg up to 2.4mg, it represents the gold standard in pharmaceutical weight loss treatment. The landmark STEP clinical trial program demonstrated unprecedented results across diverse patient populations. Wegovy works by mimicking the GLP-1 hormone, reducing appetite, slowing gastric emptying, and improving satiety signaling in the brain.
Wegovy patients lost an average of 14.9% body weight in the STEP 1 clinical trial (NEJM, 2021). Results typically begin within 4-8 weeks of starting treatment. Weight Method offers Wegovy from $297/month with virtual consultations and licensed providers.
Key Fact
STEP 1 trial: Wegovy (semaglutide 2.4mg) produced 14.9% average body weight loss over 68 weeks. 86% of participants lost ≥5% of body weight; 32% lost ≥20%. Results were sustained with continued treatment.
Source: STEP 1 — Wilding et al., NEJM 2021
STEP 1 trial: semaglutide 2.4mg produced 14.9% average weight loss over 68 weeks, with one-third of participants losing over 20% of body weight.
The STEP 1 trial — the pivotal study for Wegovy's FDA approval — showed an average weight loss of 14.9% of body weight at 68 weeks compared to 2.4% with placebo. STEP 3, which combined semaglutide with intensive behavioral therapy, achieved 16% average weight loss over the same period. Across the STEP program, approximately one-third of participants lost more than 20% of their body weight, a threshold previously achievable only through bariatric surgery. These results were consistent across age groups, genders, and baseline BMI categories. Weight Method provides the same semaglutide formulation with full clinical oversight at $297/mo.
Most patients notice reduced appetite within 1-2 weeks, visible weight loss by months 2-3, and maximum results after 12-16 months at the 2.4mg maintenance dose.
Appetite suppression and reduced food noise typically begin within 1-2 weeks of the first Wegovy injection, even at the starting 0.25mg dose. Noticeable weight loss — enough for others to observe — generally occurs by months 2-3 as dosing escalates toward the maintenance level of 2.4mg. The most rapid period of weight loss is typically between months 3-9, with results continuing to accumulate through 12-16 months. Weight loss tends to plateau around 15-17 months as the body stabilizes at a new set point. Your Weight Method provider tracks your trajectory at each stage and adjusts your plan accordingly.
Expect gradual dose increases over 16-20 weeks, mild GI side effects initially, steady weight loss of 1-2 lbs per week, and regular provider check-ins.
Based on STEP trial data, patients can expect to lose approximately 15% of their starting body weight over 68 weeks of treatment. Individual results vary — about one-third of patients exceed 20% weight loss while others may see more modest results in the 5-10% range. The medication is most effective when combined with a reduced-calorie diet and increased physical activity, as demonstrated in the STEP 3 trial. Plateaus are a normal part of the process, typically occurring around months 6-8 before weight loss resumes. Weight Method's clinical team provides regular check-ins to optimize your treatment plan and maintain momentum.
Patients with BMI 30 or higher, those who have not used GLP-1 medications before, and individuals who combine medication with lifestyle changes see the strongest results.
Patients with higher starting BMIs tend to lose a greater absolute amount of weight on Wegovy, though percentage-based losses are fairly consistent across BMI categories. Strong early appetite reduction in weeks 1-4 is a reliable predictor of robust long-term results. Individuals who engage in regular physical activity and make dietary adjustments alongside the medication consistently outperform those relying on the drug alone. The STEP trials showed similar efficacy regardless of age, sex, or race, though patients with prediabetes or insulin resistance sometimes see slightly different response patterns. Your Weight Method provider uses your early response data to tailor dosing and lifestyle recommendations.
Take our 2-minute quiz to see if you qualify for GLP-1 treatment.
Start QuizFree consultation. No commitment.